Francesca D'Angelo
Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa
D'Angelo, Francesca; Baldelli, Valerio; Halliday, Nigel; Pantalone, Paolo; Polticelli, Fabio; Fiscarelli, Ersilia; Williams, Paul; Visca, Paolo; Leoni, Livia; Rampioni, Giordano
Authors
Valerio Baldelli
Nigel Halliday
Paolo Pantalone
Fabio Polticelli
Ersilia Fiscarelli
Professor PAUL WILLIAMS PAUL.WILLIAMS@NOTTINGHAM.AC.UK
PROFESSOR OF MOLECULAR MICROBIOLOGY
Paolo Visca
Livia Leoni
Giordano Rampioni
Abstract
Copyright © 2018 American Society for Microbiology. All Rights Reserved. The long-term use of antibiotics has led to the emergence of multidrug-resistant bacteria. A promising strategy to combat bacterial infections aims at hampering their adaptability to the host environment without affecting growth. In this context, the intercellular communication system quorum sensing (QS), which controls virulence factor production and biofilm formation in diverse human pathogens, is considered an ideal target. Here, we describe the identification of new inhibitors of the pqs QS system of the human pathogen Pseudomonas aeruginosa by screening a library of 1,600 U.S. Food and Drug Administration-approved drugs. Phenotypic characterization of ad hoc engineered strains and in silico molecular docking demonstrated that the antifungal drugs clotrimazole and miconazole, as well as an antibacterial compound active against Gram-positive pathogens, clofoctol, inhibit the pqs system, probably by targeting the transcriptional regulator PqsR. The most active inhibitor, clofoctol, specifically inhibited the expression of pqs-controlled virulence traits in P. aeruginosa, such as pyocyanin production, swarming motility, biofilm formation, and expression of genes involved in siderophore production. Moreover, clofoctol protected Galleria mellonella larvae from P. aeruginosa infection and inhibited the pqs QS system in P. aeruginosa isolates from cystic fibrosis patients. Notably, clofoctol is already approved for clinical treatment of pulmonary infections caused by Gram-positive bacterial pathogens; hence, this drug has considerable clinical potential as an antivirulence agent for the treatment of P. aeruginosa lung infections.
Citation
D'Angelo, F., Baldelli, V., Halliday, N., Pantalone, P., Polticelli, F., Fiscarelli, E., Williams, P., Visca, P., Leoni, L., & Rampioni, G. (2018). Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 62(11), Article e01296-18. https://doi.org/10.1128/AAC.01296-18
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 1, 2018 |
Online Publication Date | Sep 10, 2018 |
Publication Date | Oct 10, 2018 |
Deposit Date | Dec 7, 2018 |
Publicly Available Date | Mar 11, 2019 |
Journal | Antimicrobial Agents and Chemotherapy |
Print ISSN | 0066-4804 |
Electronic ISSN | 1098-6596 |
Publisher | American Society for Microbiology |
Peer Reviewed | Peer Reviewed |
Volume | 62 |
Issue | 11 |
Article Number | e01296-18 |
DOI | https://doi.org/10.1128/AAC.01296-18 |
Keywords | Pharmacology (medical); Pharmacology; Infectious Diseases |
Public URL | https://nottingham-repository.worktribe.com/output/1177431 |
Publisher URL | https://aac.asm.org/content/62/11/e01296-18.long |
Contract Date | Dec 7, 2018 |
Files
Identification of FDA-approved drugs
(2.2 Mb)
PDF
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search